



# INDEX

This index is sorted word-by-word. Boldface page locators refer to the main entry on the subject. Italicized page locators refer to illustrations, figures, and tables.

Index created by Laurie Andriot

## A

- AA. *See* Alcoholics Anonymous (AA)
- AAAOM (American Association of Acupuncture and Oriental Medicine), 4:207
- AACI (American Association for the Cure of Inebriates), 1:98, 4:144, 305
- AAS (Addiction Admissions Scale), 1:32
- ABC (alcoholic beverage controls), 2:355
- Absenteeism, 2:275
- Absorption
- alcohol, 3:229–230
  - caffeine, 1:263
  - freebasing, 2:177
  - nicotine, 3:136–137, 4:120
  - Oxycontin, 3:226
  - pharmacokinetics, 3:221–222
- Abstinence
- acamprosate, 4:192
  - aftercare, 4:228
  - Alcoholics Anonymous, 1:125, 4:177
  - amotivational syndrome, 1:147
  - aversion therapy, 4:190–191
  - contingency management, 4:159–160
  - fetal alcohol syndrome, 2:158
  - health professionals, 3:248–249
  - Jews, 2:336
  - neurocognitive recovery, 1:395–398
  - nutritional rehabilitation, 1:403–404
  - older adults, 1:76
  - opioid dependence, 3:176
  - psychodynamic factors, 3:414–415
  - sobriety, 4:39–40
  - temperance movement, 4:86
  - See also* Relapse prevention
- Abstinence, initiation of, **4:218–219**
- Abstinence only movement, 4:308
- Abstinence violation effect (AVE), **1:1**, 3:327
- Abstinence *vs.* controlled drinking, **1:129–136**
- Abt Associates, 1:185, 186
- Abuse as risk factor, **3:424–428**, 429
- Abuse liability of drugs. *See* Drug abuse liability testing
- ACA (American Correctional Association), 3:293
- Academic achievement, 1:102, 2:41
- Acamprosate, 2:89, 4:137, **192–193**, 197
- Acceptance in twelve-step programs, 4:177, 178
- Access to Recovery (ATR), 4:256, 265–266
- Accidental poisoning, 2:353, 3:257
- Accidents and injuries, **1:7–14**, **14–18**
- alcohol-related, 3:53
  - behavioral toxicity, 1:347
  - minimum drinking age laws, 3:53
  - workplace, 2:275
- Accreditation, 3:302
- Acculturation
- Chinese Americans, 1:299
  - Hispanic Americans, 2:240–241
- Acetaldehyde dehydrogenase, 1:142
- Acetaldehyde toxicity, 1:386, 4:181
- Acetaminophen, 1:380, 3:198
- Acetylcholine, **1:18**, 3:135
- Acid. *See* LSD
- Acquired tolerance, 1:26–27
- ACTH (adrenocorticotrophic hormone), 4:304
- Action and behavioral change, 3:298, 4:170, 178
- Action on Smoking and Health (ASH), 1:253
- Action Plans on Drugs (European Union), 2:136, 137
- Acupuncture, **4:206–208**
- Acute effects
- alcohol, 1:345
  - drug abuse, 1:345–346
  - intimate partner violence and substance abuse, 2:312
  - terminology, 1:344
- Acute intoxication, 2:293, 3:239
- Acute opioid withdrawal
- naltrexone, 4:202
  - pharmacological treatment, 4:182–183
- Acute pain, 3:197
- Acute substance abuse
- intimate partner violence, 2:316–318
- Acute tolerance, 4:131
- Acute use and intimate partner violence, 2:313, 316–318
- ADAM and ADAM II, **1:185–187**, 187, 435, 2:110
- Adams, Samuel Hopkins, 3:185

- Adaptations  
 aggression, 1:70–71  
 coping buffers, 1:422  
 drug use to dependence, 1:25  
 stress, 3:431  
 treatment for older adults, 4:215, 216
- Addiction  
 biological basis, 1:242–243  
 health professionals, 3:244  
 as identity, 3:378  
 neurobiology of the transition to, 3:370–371  
 nicotine, 3:137–138, 4:105  
 physical dependence as distinct from, 4:130  
 processes of change model, 3:297–300, 298, 299  
 self-control and impulsivity, 3:371–372  
 smokeless tobacco, 4:125–126  
 tobacco, 4:102  
 welfare policy, 4:285–288
- Addiction, concepts and definitions, 1:19–28, 2:263
- Addiction, existential models of, 4:277–278
- Addiction, rhetoric of, 3:376–380
- Addiction Admissions Scale (AAS), 1:32
- Addiction* (journal), 1:28–29
- Addiction myths, 3:92–96, 93–94
- Addiction Potential Scale (APS), 1:32
- Addiction Research Center  
 ethnographic studies, 3:188–189  
 mood, measuring drug effects on, 3:354–355  
 overview, 4:250, 274
- Addiction Research Center Inventory (ARCI), 1:32, 3:356
- Addiction Research Foundation, 4:222
- Addiction Severity Index (ASI), 1:29–30, 2:189
- Addictive medications. *See* Iatrogenic addiction; Prescription drug abuse
- Addictive personality, 1:30–32
- Addictive Voice Recognition Technique (AVRT), 4:38
- ADH (alcohol dehydrogenase), 1:384, 2:85, 3:231
- ADHD. *See* Attention deficit hyperactivity disorder
- Adherence to treatment, 1:107
- ADHIB\*2 allele*, 2:337
- Adipose tissue, 3:157–158
- Adjective Rating Scales, 3:355
- Administration  
 amobarbital, 1:145–146  
 calcium carbimide, 1:265  
 disulfiram, 4:197  
 morphine, 3:80
- Administration routes, 1:406–410  
 behavior, effects on, 3:349  
 inhalants, 2:280  
 marijuana, 3:5
- Adolescents, 1:32–36, 4:209–213  
 addiction as a disease of, 1:242–243  
 Alateen, 1:84–85  
 alcohol exposure, 3:53–54  
 alcohol marketing exposure, 1:41–42  
 alcohol use, 1:38–39  
 alcohol use disorders, 2:119  
 Anslinger, Harry Jacob, policy efforts of, 1:174–176  
 boot-camp prisons, 4:25  
 Canada, 1:266–267, 269  
 Chinese Americans, 1:300–301  
 cigarette advertising, 1:53  
 cocaine use, 3:331  
 conduct disorder, 1:413–415  
 cults, 1:454  
 epidemiology of drug use, 2:124–128  
 expectancies, 2:142  
 family-based interventions, 2:147–150  
 gender gap decrease, 3:393  
 Germany, 2:210, 211  
 group therapy, 4:165  
 harmful effects of substance abuse, 1:348  
 Hispanic Americans, 2:240  
 inhalant use, 2:285  
 Internet, influence of the, 2:309–310  
 Italy, 2:326  
 Jewish, 2:337  
 juvenile drug courts, 2:57–58  
 Kenya, 2:344  
 LSD, 2:373  
 MINI-KID, 3:52  
 minimum drinking age laws, 3:53–57  
 motivational interviewing and brief interventions, 4:172  
 music, 3:91–92  
 Netherlands, 3:120, 121  
 nicotine addiction, 3:139  
 Nordic countries, 3:152  
 Office of National Drug Control Policy, 4:265  
 opioid use, 3:175  
 pathological gambling, 2:192  
 race/ethnicity, 3:419–420  
 rave, 3:320–323  
 religion, 3:329, 330, 332  
 sexual development, 4:18–19  
 smokeless tobacco use, 4:125  
 smoking, 1:52–53, 4:110  
 Strategic Planning Framework, 4:254  
 Students Against Destructive Decisions (SADD), 4:65–67  
 Toughlove, 4:133–134
- zero tolerance policy, 4:318–319  
*See also* Monitoring the Future
- Adolph Coors, 1:40
- Adoption studies  
 alcoholism and gender, 3:391  
 genetic risk factors, 3:397
- Adrenal glands, 1:366–367
- Adrenaline. *See* Norepinephrine
- Adrenocorticotrophic hormone (ACTH), 4:304
- ADSS (Alcohol and Drug Services) study, 3:303
- Adult children of alcoholics, 1:36–38, 222, 332–333
- Adulteration methods, drug testing, 2:86–87
- Advance recovery, 4:178–179
- Adverse consequences of chronic sedative use, 4:5–9
- Adverse effects. *See* Complications; Side effects
- Advertising, alcohol, 1:38–45  
 Distilled Spirits Council, 2:25, 26  
 European Union, 2:134  
 France, 2:173  
 sports, 4:57–59
- Advertising, prescription drug, 1:45–49, 4:310
- Advertising, tobacco, 1:50–55  
 Britain, 1:251  
 cigarettes, 4:98–99, 107–108  
 European Union, 2:132–133  
 France, 2:173–174  
 Germany, 2:210  
 Italy, 2:330  
 Nordic countries, 3:151  
 regulation, 2:357  
 smokeless tobacco, 4:126, 127  
 weight, 4:129
- Advisory Committee on Immunization Practices, 1:381
- Aesthetic use of anabolic steroids, 1:164–185
- AFDC (Aid to Families with Dependent Children), 4:285–286
- Affect regulation model, 3:409–410
- Affective disorders  
 gender, 3:392  
 marijuana, 3:7–8  
 military, drug and alcohol abuse in the, 3:47  
 substance use disorders with, 1:388–390
- Affective Education programs, 3:275
- Affiliation, 1:125–126
- Affordable housing, 2:247
- Afghanistan, 1:56–58  
 crop control policies, 1:446–451  
 Middle East drug production, 3:43  
 terrorism and drugs, 4:90–91

- Africa, **1:58–63**  
 alcohol consumption, 1:92  
 khat, 2:344–349
- African American Extended Family Program, 1:67–68
- African Americans, **1:63–69**  
 gangs, 2:197–198  
 opium, 3:185  
*See also* Race/ethnicity; Racial profiling
- African National Congress, 4:49
- Aftercare, **4:227**  
 coerced treatment, 1:334–335  
 family-based interventions, 2:149  
 long-term *vs.* brief therapy, 4:167  
 Minnesota Model, 4:170  
 Narcotic Addict Rehabilitation Act programs, 3:100  
 Washingtonian movement, 4:143
- Afternoon gap, 1:249
- Age  
 alcohol consumption, 1:73  
 benzodiazepines, adverse consequences of, 4:7  
 high-rate serious offenders, 1:440  
 intimate partner violence, 2:312  
 onset of alcohol consumption, 2:117–118, 119  
 pathological gambling, 2:192  
 psychological effects of chronic alcohol abuse, 1:102  
 sensation seeking and impulsivity, 3:422  
*See also* Aging; Minimum drinking age laws; Underage drinking
- Age of Exploration, 1:93
- Agencies in drug law enforcement and supply control, **4:244–248**
- Agencies supporting substance abuse prevention and treatment, **4:248–250**
- Agencies supporting substance abuse research, **4:250–252**
- Aggression, **1:69–72**  
 alcohol use, 1:102–103, 430–433, 2:317–318  
 anabolic steroids, 1:165–166  
 driving under the influence, 2:35  
 phencyclidine (PCP), 3:240–241
- Aging, **1:73–81**
- Agonists, **1:81–82**  
 melatonin, 4:8  
 opioid detoxification, 4:220–221  
 opioids, 3:162  
 partial, 1:219, 3:162
- Agroyungas project, 1:235
- Aid to Families with Dependent Children (AFDC), 4:285–286
- AIDS. *See* HIV/AIDS
- Aiken, Doris, 3:333
- Akihito, Emperor, 4:100
- Al Qaeda, 4:91
- Al-Anon, **1:82–84**
- Alateen, **1:84–85**
- Alcohol, **1:85–104**  
 amygdala, 1:162  
 chemistry and pharmacology, 1:85–90  
 cocaine combined with, 1:319, 324–325, 2:61  
 dopamine, 1:242  
 as a drug, 2:88–89  
 drug testing, 2:79–81  
 laudanum compounds, 2:351–353
- Alcohol, accidents and injuries from, **1:7–14**, 8, 14–17
- Alcohol, allergies to, **1:141–143**
- Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA), 3:206
- Alcohol, history of drinking (international), **1:90–96**
- Alcohol, history of drinking (United States), **1:96–101**
- Alcohol, Jews and, **2:335–339**
- Alcohol, pharmacokinetics of, 3:222, 228, **228–232**, 230, 231
- Alcohol, prohibition of. *See* Prohibition of alcohol
- Alcohol, psychological consequences of chronic abuse, **1:102–104**
- Alcohol, psychomotor effects of, **3:309–312**
- Alcohol, Smoking and Substance Involvement Screening Test (ASSIST), **1:120**
- Alcohol- and drug-free housing, **1:114–120**
- Alcohol abuse and alcoholism  
 abstinence monitoring among health professionals, 3:248  
 accidents and injuries, 1:12  
 Africa, 1:61  
 age, 1:73  
 Al-Anon, 1:82–84  
 Alateen, 1:84–85  
 Alcohol Use Disorders Identification Test (AUDIT), 1:120–122  
 alcoholism subtypes, 1:23  
 aversion therapy, 4:190–191  
 benzodiazepines, 1:222  
 bone mass, 1:368  
 carbohydrate metabolism, 1:367  
 cardiovascular effects, 1:351, 356–360  
 codependence, 1:331–333  
 cognition, 1:363  
 consumption, 3:285  
 controlled drinking, 1:129–134  
 costs, 1:43  
 craving, 1:425  
 definition, 1:20, 39  
 drug interactions and alcohol, 2:63  
 elimination rates, 3:231  
 endocrine system effects, 1:365  
 epidemiology, 2:125  
 European Union, 2:135  
 existential models, 4:277–278  
 gastrointestinal tract and pancreas effects, 1:352–353  
 gender, 3:391–392  
 hallucinogen use for treatment, 2:226  
 harmful effects, 1:346–348  
 health effects, 1:87–88  
 heart and blood vessel complications, 1:409  
 hematologic effects, 1:354–355  
 Hispanic Americans, 2:240–241  
 homelessness, 2:243–248  
 immunologic complications, 1:369–371  
 International Classification of Diseases (WHO), 2:293  
 as irreversible disease, 1:131  
 Jews, 2:337  
 liver diseases, 1:376–380  
 liver effects, 1:353  
 medical detoxification, 4:220  
 memory, 3:18–19  
 metabolic effects, 1:354  
 metabolic liver complications, 1:383–386  
 metabolism, 2:74  
 Michigan Alcoholism Screening Test, 3:39–40  
 military, 3:44–49  
 models, 3:60–66  
 moderate *vs.* excessive drinking, 1:386  
 National Council on Alcoholism and Drug Dependence, 3:105–106  
 neurologic effects, 1:348–349, 394–396, 395  
 nutritional effects, 1:354, 401–405  
 older adults, 1:75  
 pharmacological research, 3:344  
 pharmacological treatment overview, 4:180–182  
 plants used in fermentation process, 3:252  
 polydrug use, 1:325  
 premodern treatment, 4:142–146  
 productivity, 3:300–301  
 public intoxication, 3:313–315  
 renal effects, 1:355  
 reproduction and pregnancy, 1:366  
 respiratory system effects, 1:352

- Alcohol abuse and alcoholism  
(*continued*)
- Semi-Structured Assessment for Drug Dependence and Alcoholism, 4:10–11
  - Semi-Structured Assessment for the Genetics of Alcoholism, 4:11–12
  - skeletal muscle effects, 1:355
  - sobriety, 4:39–40
  - Structured Clinical Interview for DSM-IV, 4:63
  - suicide, 4:71–74
  - T-ACE, 4:79–80
  - thyroid gland, 1:367–368
  - toxic effects of excessive drinking, 1:87–88
  - welfare policy, 4:285–288
  - withdrawal, 4:131, 293
  - Woman's Christian Temperance Union, 4:305–308
  - women, 4:309–312
- Alcohol abuse and alcoholism, economic costs of, **2:102–104**
- Alcohol abuse and alcoholism, psychological consequences of, **1:102–104**
- Alcohol abuse and intimate partner violence, **2:311–322**
- Alcohol advertising, **1:38–45**
- Distilled Spirits Council, 2:25, 26
  - France, 2:173
  - sports, 4:57–59
- Alcohol and aging, **1:73–81**, 78
- Alcohol and AIDS, **1:104–111**
- Alcohol and crime, **1:429–434**
- Alcohol and drug interactions, 2:60–61, **62–65**
- Alcohol and Drug Services (ADSS) study, 3:303
- Alcohol antagonists, **1:177–180**
- Alcohol beverage control. *See* Legal regulation of drugs and alcohol; Prohibition
- Alcohol chemistry and pharmacology, **1:85–90**
- Alcohol Concern, 1:250
- Alcohol consumption, 3:283, 284
- acute effects, 1:345
  - advertising, 1:41
  - Africa, 1:59, 60
  - aggression, 1:71
  - Asian and Pacific Islander Americans, 1:299
  - Australia, 1:195–196
  - beer consumption, 1:210–211, 211
  - beneficial effects, 1:357
  - Canada, 1:266, 267
  - cancer, 1:269–271, 270
  - Chinese Americans, 1:299, 301
  - creativity, 1:429
  - drinking, history of (international), 1:90–96
  - drinking, history of (United States), 1:96–100
  - driving under the influence, 2:34–35, 38
  - Eastern Europe, 2:99
  - epidemic use, 2:108, 109, 110
  - epidemiology, 2:124
  - European Union, 2:134–135
  - expectancies, 2:141–144
  - France, 2:170–171, 172
  - gang members, 2:197, 198
  - gender, 2:203, 3:391–392
  - Germany, 2:209–210, 212
  - guidelines for older adults, 1:74–75
  - high-risk use, 4:254
  - high school seniors' self-reports, 3:56, 57
  - historical trends, 2:112–114, 113
  - information sources, 3:380
  - Ireland, 2:322–323
  - Italy, 2:327
  - Japan, 2:333–334
  - khat combined with, 2:347
  - Maternal alcohol consumption, 4:79–80
  - methadone maintenance programs, 3:26
  - Mexico, 3:36
  - military, 3:44–45
  - minimum drinking age laws, 3:53–57
  - moderate *vs.* excessive drinking, 1:386
  - Monitoring the Future survey, 3:73–74
  - National Institute on Alcoholism and Alcohol Abuse Guidelines*, 1:356
  - Netherlands, 3:120–121
  - Nigeria, 3:142–153
  - Nordic countries, 3:146–150, 153
  - per capita, 1:42
  - Prohibition, 3:304–305, 305
  - Rohypnol and, 3:436
  - sexual response, 4:15–16
  - sleep effects, 4:34
  - South Africa, 4:48–49
  - Spain, 4:51
  - sports, 4:57–59
  - total consumption model, 3:283–286
  - women, 4:309–310
  - See also* Drinking behavior
- Alcohol consumption, Britain, **1:248–251**
- Alcohol consumption and productivity, **3:300–302**
- Alcohol dehydrogenase (ADH), 1:384, 2:85, 3:231
- Alcohol-exposed infants, **1:111–114**
- Alcohol-free housing, **1:114–120**
- Alcohol habit, 1:20
- Alcohol-induced myopia theory, 1:105
- Alcohol myopia, 4:278
- Alcohol policy
- Bolivia, 1:236
  - European Union, 2:134–135
  - Ireland, 2:323, 325
  - Italy, 2:329–330
  - Nordic countries, 3:147–150
  - South Africa, 4:47–49
  - Soviet Union, 2:101
  - Spain, 4:53–54
  - See also* Legal regulation of drugs and alcohol
- Alcohol policy, Britain, **1:248–251**
- Alcohol-related birth defects (ARBD), 2:155, 4:79
- Alcohol sensitivity, 2:337
- Alcohol testing, 2:84–85
- Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS), **1:192–194**
- Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV, 2:8
- Alcohol use disorders (AUDs), **2:112–122**, 117
- adult children of alcoholics, 1:36–37
  - Alcohol Use Disorder and Associated Disabilities Interview Schedule, 1:192–194
  - Alcohol Use Disorders Identification Test, 1:120–122
  - comorbidity with antisocial personality disorder, 1:181–182
  - controlled drinking *vs.* abstinence, 1:129–134
  - Division of Epidemiology and Prevention Research, NIAAA, 4:258
  - Division of Metabolism and Health Effects, NIAAA, 4:258–259
  - Division of Treatment and Recovery Research, NIAAA, 4:259
  - Jews, 2:337
- Alcohol Use Disorders Identification Test (AUDIT), **1:120–122**
- Alcohol withdrawal, **4:291–294**
- delirium tremens, 2:2
  - symptoms, 1:89, 2:13
  - treatment, 1:89, 4:135–136
  - Washingtonian movement, 4:143
- Alcoholic beverage controls (ABC), 2:355
- Alcoholic beverage industry, 4:57–59
- Alcoholic beverages
- distillation, 2:21–22
  - drugs producing antabuse-like reactions with, 1:75

- Kenya, 2:341–342  
 Middle East, 3:40–41  
 Peru, 3:211–212  
 sales, 1:43  
*See also specific types*
- Alcoholic cardiomyopathy, 1:358, 409  
 Alcoholic dementia, 1:103–104, 349, 363, 3:19  
 Alcoholic hallucinosis, 2:220–221  
 Alcoholic heart muscle disease, 1:358  
 Alcoholic Rehabilitation Act of 1968, 3:314  
 Alcoholics Anonymous (AA), **1:122–129, 124**  
 abstinence, 1:130, 131  
 African American participation, 1:65  
 alcohol- and drug-free housing, 1:116  
 alcohol dependence treatment, 1:90  
 controversy, 4:173–174  
 cults, 1:454  
 discourse, 3:377–378  
 disease of the self model, 3:64–65  
 drinking, history of, 1:100  
 influence on modern treatment, 4:150–151  
 Italy, 2:329  
 methadone maintenance programs, 3:28  
 Minnesota Model, 4:169–171  
 outpatient *vs.* inpatient settings, 4:229–230  
 Rational Recovery as alternative to, 4:38  
 Secular Organizations for Sobriety as alternative to, 4:4  
 sobriety, 4:39  
 twelve-step and disease model approach, 4:177
- Alcoholism, abstinence *vs.* controlled drinking, **1:129–136**  
 Alcoholism, origin of the term, **1:136–141**  
 Alcoholism movement, 1:138  
*Alcoholismus chronicus* (Huss), 1:137  
 Aldehyde dehydrogenase (ALDH), 4:136  
 Alexander the Great, 1:56–58, 91  
 Alkanes, 2:280–281  
 Alkyl, 1:164  
 All Schedule Prescription Electronic Reporting Program, 3:268, 270  
 Allergies to alcohol and drugs, **1:141–143**  
 Alles, Gordon, 1:154  
 Allostasis, 2:141, 3:225–226  
 Alpius, Prosper, 3:41  
 Alternative development, 1:447–448, 450
- Alternatives to twelve-step programs, 4:174–175  
*Amanita muscaria*, 2:166–167  
 Amantadine, **1:143–144, 143–145, 4:184**  
 Amazon region, 1:200–202  
 Ambivalence and relapse prevention, 4:226  
 Ambrose, Myles, 3:160, 4:238  
 Ambulatory care. *See* Outpatient treatment  
 Amde Zion, 2:345  
 American Association for the Cure of Inebriates (AACI), 1:98, 4:144, 305  
 American Association of Acupuncture and Oriental Medicine (AAAOM), 4:207  
 American Correctional Association (ACA), 3:293  
 American Law Institute, 3:2  
 American Medical Association  
 addiction medicine, recognition of, 1:144  
 opioid dependence, 3:174  
 American Psychiatric Association, 2:15  
 American Psychological Association, 3:302  
 American Society for the Promotion of Temperance, 1:98  
 American Society of Addiction Medicine (ASAM), **1:144–145, 3:302, 4:228–229**  
 American Temperance Society, 1:98, 4:85–86  
 American Tobacco Company, 4:106  
 AMERSA (Association for Medical Education and Research in Substance Abuse), 1:190  
 Amezcu-Contreras organization, 3:38  
 Aminergic transmitters, 3:129–130  
 Amino acid transmitters, 3:129  
 Amnesia, 3:19  
 Amnestic disorder, 2:294  
 Amobarbital, **1:145–146**  
 Amotivational syndrome, **1:146–148, 2:92**  
 Amphetamine epidemics, 1:148–149, **153–162**  
 Amphetamines, **1:148–153, 155, 159, 2:373**  
 aggression, 1:71–72  
 Australia, 1:197–198  
 Britain, 1:246  
 crime involving, 1:438  
 effects, 3:383–387, 384  
 epidemiology, 2:127  
 international supply system, 2:305–306
- low-birth-weight, 1:405  
 media, 3:14–15  
 memory, 3:20–21  
 nutritional complications, 1:404  
 overview of effects, tolerance and withdrawal, 2:91  
 prescription drug abuse, 3:267  
 Spain, 4:53
- Amygdala, **1:162**  
 Amyl nitrite, 2:281  
 Anabolic steroids, *1:163, 163–168, 4:56*  
 Analgesic ladder, 1:305  
 Analgesics, **1:168, 3:195–196, 196–201, 199**  
 chronic pain management, 1:305–306  
 codeine, 1:331  
 heroin, 2:237  
 hydromorphone, 2:251  
 meperidine, 3:21–22  
 morphine, 3:79–81  
 opioids, 3:161–162, 387  
 opium, history of, 3:184  
 oxycodone, 3:192  
 Oxymorphone, 3:193–194  
 prescription drug abuse, 3:265  
 propoxyphene, 3:307  
 Analytic methods, 2:80  
 Anaphylactic reactions to alcohol, 1:142  
 Anaphylaxis, 1:143  
 Anastas, Robert, 4:65  
 Ancient cultures  
 civil codes, 2:359  
 laudanum, 2:351–352  
*An Ancient Physician's Legacy to His Country* (Dover), 2:31  
 Andean strategy, 1:343  
 Anderson, Dan, 4:169  
 Androstenedione, 1:163  
 Anecdotal observations, 3:334–335  
 Anesthesia, 1:205, 2:255  
 Anesthesiologists, 3:243–244  
 Anesthetics  
 analgesics as distinct from, 1:168  
 cocaine, 1:319, 327  
 inhalants, 2:281–282  
 Angel dust. *See* Phencyclidine (PCP)  
 Anhedonia, 1:151, **168–169**  
 Animal models, **3:359–375**  
 addiction as compulsive drug-seeking behavior, 1:242  
 aggression and drugs, 1:70–71  
 alcohol and AIDS, 1:105–107  
 alcohol use during pregnancy, 1:366  
 amphetamines, 1:151  
 amygdala, 1:162  
 analgesics, 3:196